<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20202" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cyclosporine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tapia</surname>
            <given-names>Carolina</given-names>
          </name>
          <aff>Instituto Mexicano del Seguro Social</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Carolina Tapia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20202.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cyclosporine is an immunosuppressive agent used to treat organ rejection post-transplant. It also has use in certain other autoimmune diseases, treatment of organ rejection in kidney, liver, and heart allogeneic transplants, rheumatoid arthritis when the condition has not adequately responded to methotrexate. Also, it is a second-line agent for ALS and graft vs. host disease. It also has other FDA and non-FDA-approved indications. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of cyclosporine, pertinent for interprofessional team members in treating conditions where cyclosporine is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of cyclosporine.</p></list-item><list-item><p>Review the FDA and non-FDA-approved indications for cyclosporine.</p></list-item><list-item><p>Explain the importance of monitoring for toxicity with cyclosporine.</p></list-item><list-item><p>Summarize the importance of interprofessional communication in improving care coordination among the interprofessional team when initiating cyclosporine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20202">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20202.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cyclosporine is an immunosuppressive agent used to treat organ rejection post-transplant. It also has uses in certain other autoimmune diseases.<xref ref-type="bibr" rid="article-20202.r1">[1]</xref><xref ref-type="bibr" rid="article-20202.r2">[2]</xref><xref ref-type="bibr" rid="article-20202.r3">[3]</xref><xref ref-type="bibr" rid="article-20202.r4">[4]</xref><xref ref-type="bibr" rid="article-20202.r5">[5]</xref></p>
        <p>
<bold>FDA approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In solid organ transplantation, it has clinical use to treat organ rejection in kidney, liver, and heart allogeneic transplants.</p>
          </list-item>
          <list-item>
            <p>In patients with rheumatoid arthritis, it is indicated when the disease has not adequately responded to methotrexate.</p>
          </list-item>
          <list-item>
            <p>For psoriasis, indications include the treatment of adult, nonimmunocompromised patients with severe, recalcitrant, plaque psoriasis who have not responded to at least one systemic therapy.</p>
          </list-item>
          <list-item>
            <p>In patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig disease), cyclosporin&#x000a0;is approved to treat&#x000a0;amyotrophic lateral sclerosis and its variants.</p>
          </list-item>
          <list-item>
            <p>In nephrotic syndrome, it is indicated to treat focal segmental glomerulosclerosis not responding to corticosteroids.</p>
          </list-item>
          <list-item>
            <p>In individuals with graft vs. host disease (GVHD), it prevents and treats the disease.</p>
          </list-item>
          <list-item>
            <p>In the case of uveitis, cyclosporin is indicated for refractory posterior uveitis and Behcet disease.</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic conjunctivitis, keratoconjunctivitis, Langerhans cells histiocytosis, ocular graft vs. host disease, autoimmune hepatitis, Duchenne muscular dystrophy, ulcerative colitis, pure red cell aplasia, and Henoch Sch&#x000f6;nlein purpura nephritis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20202.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cyclosporine&#x000a0;works to suppress cell-mediated immune reactions. Research has detected no effects on phagocytic function in animals, and it does not cause bone marrow suppression in animal or human models.<xref ref-type="bibr" rid="article-20202.r6">[6]</xref><xref ref-type="bibr" rid="article-20202.r7">[7]</xref></p>
        <p>The mechanism of action of cyclosporine&#x000a0;is as a calcineurin inhibitor, a cytochrome P450 3A4 inhibitor, and a P-glycoprotein inhibitor. Cyclosporin A (CsA) inhibits the synthesis of interleukins (IL), including IL-2, which is essential for the self-activation of T lymphocytes (LT) and their differentiation. Cyclosporine is effective due to specific and reversible inhibition of immunocompetent lymphocytes in the G0 and G1-phase of the cell cycle. The T-helper cell is the primary target, although it may also suppress T-suppressor cells. The LT-B-lymphocyte (LB) co-operation is essential for activation of LB; the latter also gets inhibited. In addition, research has demonstrated that CsA had an inhibiting effect on CD4+ CD25+ Tregs, which might block the host immune tolerance potentiality.</p>
        <p><bold>Metabolism:</bold> Via hepatic CYP3A4 and is metabolized&#x000a0;into a pair of hydroxylated derivatives (AM1 and AM9) and one N-methylated derivative (AM4N).</p>
        <p><bold>Enzymes inhibited:</bold> CYP3A4 and P-glycoprotein.</p>
        <p><bold>Half-Life:</bold> 8.4&#x000a0;to 27 hours: The time to peak blood cyclosporine concentrations (Tmax) ranges from 1.5 to 2 hours following oral administration of cyclosporine oral solution USP modified.</p>
        <p><bold>Clearance:</bold> 5 to 7 mL/min/kg in patients who are recipients of renal or liver allografts&#x000a0;while appearing to be somewhat slower in cardiac transplant patients.</p>
        <p><bold>Excretion:</bold> Mainly bile and feces.</p>
        <p><bold>Factors known to influence&#x000a0;absorption:</bold>&#x000a0;Time post-transplant, bile flow, dietary composition, gastrointestinal state, liver function, small bowel length, and vehicle.</p>
      </sec>
      <sec id="article-20202.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosing for Organ Transplant in Adults</bold>
</p>
        <p>
<bold>Oral</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Four to 12 hours pre-transplant: 14 to 18 mg/kg by mouth for one dose.</p>
          </list-item>
          <list-item>
            <p>One to two weeks post-transplant: 5 to 15 mg/kg per day by mouth divided twice a day.</p>
          </list-item>
          <list-item>
            <p>Reduce the dose by 5% per week until 5 to 10 mg/kg per day by mouth divided twice per day.</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous (IV) (maximum concentration 2.5 mg/dL)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Four to 12 hours pre-transplant IV: 5 to 6 mg/kg IV for one dose over 2 to 6 hours.</p>
          </list-item>
          <list-item>
            <p>Post-transplant until the patient can tolerate oral therapy: 2 to 10 mg/kg IV once per day.</p>
          </list-item>
          <list-item>
            <p>Adjust dosage according to trough levels.</p>
          </list-item>
        </list>
        <p><bold>Focal segmental glomerulosclerosis:</bold> Oral 3 mg/kg/day every 12 hours.</p>
        <p><bold>Rheumatoid arthritis:</bold> Oral (modified), initially: 2.5 mg/kg per day every 12 hrs, increase 0.5 to 0.75 mg/kg per day after eight weeks if the response has not been effective. Maximum dose: 4 mg/kg per day.</p>
        <p><bold>Psoriasis:</bold> Oral (modified), initially: 2.5 mg/kg per day every 12 hours, increase 0.5 mg/kg per day after four weeks if the response has not been effective. Maximum dose: 4 mg/kg per day.</p>
      </sec>
      <sec id="article-20202.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cardiovascular: Hypertension, arrhythmia.</p>
        <p>Renal: Decreases glomerular filtration rate (GFR) due to an increased tone of the glomerular afferent arterioles. Serum creatinine concentration rises and decreases creatinine clearance. The undesirable effects correlate with the duration of treatment and dose.</p>
        <p>Endocrinological and metabolic: Dyslipidemia (predisposing factors such as hypertension), hypomagnesemia, hyperkalemia, gynecomastia, hypertrichosis.</p>
        <p>Neurotoxicity: There have been reports of convulsions, especially in combination with high dose methylprednisolone, encephalopathy, anxiety, headache, and fever.</p>
        <p>Others: There is an increased risk of developing skin and lymphoproliferative malignancies in cyclosporine-treated psoriasis patients.</p>
        <list list-type="bullet">
          <list-item>
            <p>Increase in the occurrence of malignant lymphomas.</p>
          </list-item>
          <list-item>
            <p>Increase the level of inflammatory cytokines such as TNF-alfa.</p>
          </list-item>
          <list-item>
            <p>Increase the infection risk.&#x000a0;<xref ref-type="bibr" rid="article-20202.r8">[8]</xref><xref ref-type="bibr" rid="article-20202.r9">[9]</xref><xref ref-type="bibr" rid="article-20202.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20202.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Drugs: amphotericin B deoxycholate, atorvastatin, bosentan, cidofovir, elbasvir/grazoprevir, flibanserin, lomitapide, mifepristone, neomycin oral, pitavastatin, saquinavir, simvastatin, sitaxentan, tacrolimus</p>
        <p>BCG</p>
        <p>Attenuated vaccine</p>
        <p>Hypersensitivity to cyclosporine or any of the ingredients of the formulation (such as polyoxyethylated castor oil)</p>
        <p>Active infection</p>
        <p>Patients with impaired renal function</p>
        <p>Asthma</p>
        <p>History of blood dyscrasias</p>
        <p>Uncontrolled hypertension</p>
        <p>In the case of psoriasis: Concomitant PUVA therapy, ultraviolet B (UVB) radiation, coal tar, methotrexate, other immunosuppressants&#x000a0;<xref ref-type="bibr" rid="article-20202.r11">[11]</xref></p>
      </sec>
      <sec id="article-20202.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient's BUN creatinine ratio, magnesium levels, and blood pressure require monitoring while on therapy. Uric acid monitoring is debatable. Therapeutic monitoring of cyclosporine in transplant patients is a valuable tool in adjusting drug dosage to prevent acute rejection, nephrotoxicity, and predictable dose-dependent adverse reactions. The ideal therapeutic range of cyclosporine in whole blood is as follows:&#x000a0;</p>
        <p>Kidney transplant:&#x000a0;200 to 400 ng/ml in the first week after transplantation; 125 to 275 ng/ml in the second week to the sixth-month post-transplantation; 100 to 150 ng/ml in the seventh to the twelfth-month post-transplantation; and 75 to 160 ng/ml&#x000a0;one year after transplantation&#x000a0;(residual concentration predose).</p>
        <p>Heart transplant:&#x000a0;250 to 350 ng/mL in the first&#x000a0;six months; 100 to 200 ng/mL&#x000a0;six months to one year after transplantation (residual concentration predose).</p>
        <p>Liver transplant:&#x000a0;250 to 350 ng/mL for the first&#x000a0;six months; 100&#x000a0;to 200 ng/mL&#x000a0;six months to one year after transplantation (residual concentration predose).</p>
        <p>The range between effective cyclosporine concentrations and the concentrations associated with serious toxicity is fairly narrow. Sub-optimal doses or concentrations can lead to therapeutic failure or severe toxicity. Cyclosporine is subject to therapeutic monitoring based on pharmacokinetics measures. The medication&#x000a0;has low-to-moderate within-subject variability.</p>
      </sec>
      <sec id="article-20202.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In the event of toxicity, establishing a patent airway is a priority. There is a need to watch for signs of respiratory insufficiency and provide ventilation assistance if needed. Also, the healthcare provider needs to monitor for shock and treat if necessary. They should anticipate seizures and treat if necessary, and initiate supportive and symptomatic treatment. When overdosage occurs in patients prescribed cyclosporine&#x000a0;therapy, the&#x000a0;healthcare provider&#x000a0;may withhold the drug for a few days or initiate alternate-day therapy until the patient stabilizes.<xref ref-type="bibr" rid="article-20202.r12">[12]</xref></p>
        <p>Hemodialysis only eliminates 1% of the dose. Monitoring serum CsA levels is mandatory, and patients may need multiple dose adjustments during the treatment period. The CVC (central venous catheter) line is not used to infuse CsA and can be safely used to collect blood samples for serum CsA levels. The procedure can be performed immediately after interrupting the infusion if using the appropriate technique for discarding 5 mL of blood.</p>
        <p>Drugs that can decrease CsA levels include rifampicin, rifabutin, isoniazid, barbiturates, phenytoin, carbamazepine,&#x000a0;intravenous trimethoprim,&#x000a0;intravenous sulfadimidine, imipenem, cephalosporins, terbinafine, ciprofloxacin, ticlopidine, octreotide, and nefazodone. Conversely, drugs&#x000a0;that can increase CsA levels include verapamil, diltiazem, amlodipine, nicardipine, ketoconazole, fluconazole, itraconazole, erythromycin, clarithromycin, azithromycin, saquinavir, indinavir, nelfinavir, ritonavir, methylprednisolone.</p>
      </sec>
      <sec id="article-20202.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cyclosporine is a widely used immunosuppressive drug, especially in transplant patients. The majority of patients on cyclosporine can be followed as outpatients by the nurse practitioner, primary care provider, internist, and specialist. The clinical staff must&#x000a0;monitor cyclosporine levels regularly to&#x000a0;prevent acute rejection, nephrotoxicity, and predictable dose-dependent adverse reactions.</p>
        <p>Further, the pharmacist and nurse should educate the patient on potential complications of the drug and the need to follow up regularly. Pharmacists should verify dosing, and also, given the extensive drug-drug interaction list for cyclosporine, thorough medication reconciliation is in order, with any red flags reported promptly to the rest of the healthcare team. Nursing can monitor both for treatment effectiveness and the adverse effects of the medication, alerting the treating physician of any concerns. Finally, patients on cyclosporine are at a slight risk of lymphoproliferative malignancies and infections; thus, a thorough history and physical exam are vital at each clinic visit.</p>
        <p>Cyclosporine therapy has a much higher opportunity for patient success with the communication and collaboration of an interprofessional healthcare team. [Level 5]</p>
      </sec>
      <sec id="article-20202.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20202">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20202/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20202">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20202.s11">
        <title>References</title>
        <ref id="article-20202.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pradier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papaserafeim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rietveld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaestel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gruaz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vonarburg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spirig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Puga Yung</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Seebach</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions <italic>in vitro</italic>.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>556</fpage>
            <pub-id pub-id-type="pmid">30972058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <source>Pharmacoeconomic Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2018</year>
            <month>08</month>
            <pub-id pub-id-type="pmid">30958668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Prevention of complications from use of conventional immunosuppressants: a critical review.</article-title>
            <source>J Nephrol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>851</fpage>
            <page-range>851-870</page-range>
            <pub-id pub-id-type="pmid">30927190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xin</surname>
                <given-names>GLL</given-names>
              </name>
              <name>
                <surname>Khee</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Chellian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kunnath</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Nammi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hansbro</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Dua</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chellappan</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.</article-title>
            <source>Curr Diab Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>23</day>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">30905013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QM</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.</article-title>
            <source>Br J Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>181</volume>
            <issue>6</issue>
            <fpage>1166</fpage>
            <page-range>1166-1176</page-range>
            <pub-id pub-id-type="pmid">30903622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liddicoat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lavelle</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Modulation of innate immunity by cyclosporine A.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2019</year>
            <month>May</month>
            <volume>163</volume>
            <fpage>472</fpage>
            <page-range>472-480</page-range>
            <pub-id pub-id-type="pmid">30880061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uliana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taddei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Virdis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hypertension: Know the problem to know how to deal with it.</article-title>
            <source>Vascul Pharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>115</volume>
            <fpage>84</fpage>
            <page-range>84-88</page-range>
            <pub-id pub-id-type="pmid">30822569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics.</article-title>
            <source>Indian J Pediatr</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>7</issue>
            <fpage>590</fpage>
            <page-range>590-594</page-range>
            <pub-id pub-id-type="pmid">30937723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Grgic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chandraker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Novel Targets of Immunosuppression in Transplantation.</article-title>
            <source>Clin Lab Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-169</page-range>
            <pub-id pub-id-type="pmid">30709504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arslansoyu Camlar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soylu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kavuk&#x000e7;u</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine in Pediatric Nephrology.</article-title>
            <source>Iran J Kidney Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>319</fpage>
            <page-range>319-330</page-range>
            <pub-id pub-id-type="pmid">30595561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soleymani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vassantachart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: A Critical Appraisal and Comprehensive Review.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-301</page-range>
            <pub-id pub-id-type="pmid">26954314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20202.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patocka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nepovimova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuca</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine A: Chemistry and Toxicity - A Review.</article-title>
            <source>Curr Med Chem</source>
            <year>2021</year>
            <volume>28</volume>
            <issue>20</issue>
            <fpage>3925</fpage>
            <page-range>3925-3934</page-range>
            <pub-id pub-id-type="pmid">33023428</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
